BioCentury | Aug 11, 2018
Product Development

Exacerbation management

Based on work spearheaded by the Cystic Fibrosis Foundation, Corbus Pharmaceuticals Holdings Inc. will be the first company to attempt to gain approval in CF based on pulmonary exacerbations instead of FEV1. The company is...
BioCentury | Aug 3, 2018
Clinical News

Celtaxsys planning Phase III program for CF candidate

Celtaxsys Inc. (Atlanta, Ga.) said it hopes to start Phase III testing in 2H19 evaluating acebilustat (CTX-4430) to treat cystic fibrosis after reporting data from the Phase II EMPIRE-CF trial of the candidate in the...
BioCentury | Aug 2, 2018
Clinical News

Celtaxsys planning Phase III program for CF candidate

Celtaxsys Inc. (Atlanta, Ga.) said it hopes to start Phase III testing in 2H19 evaluating acebilustat (CTX-4430) to treat cystic fibrosis after reporting data from the Phase II EMPIRE-CF trial of the candidate in the...
BioCentury | Jan 19, 2018
Clinical News

Eiger discontinues ubenimex for PAH

Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) discontinued development of ubenimex to treat pulmonary arterial hypertension (PAH). The company made the decision after the product missed the primary endpoint in the Phase II LIBERTY trial in the indication....
BioCentury | Jan 16, 2018
Clinical News

Phase II PAH readout sinks Eiger shares

Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) lost $7.90 (49%) to $8.10 Tuesday after discontinuing development of ubenimex to treat pulmonary arterial hypertension. The company made the decision after the product missed the primary endpoint in the Phase...
BioCentury | May 19, 2017
Clinical News

Eiger completes enrollment in Phase II to treat PAH

Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) completed enrollment of 61 patients with pulmonary arterial hypertension (PAH) in the North American Phase II LIBERTY trial evaluating Bestatin ubenimex plus standard of care (SOC). Patients in the double-blind, placebo-controlled...
BioCentury | Feb 1, 2017
Clinical News

Bestatin: LIBERTY2 extension study started

Eiger began the open-label LIBERTY2 extension study of oral Bestatin for ≥24 weeks in about 45 patients who completed the double-blind, placebo-controlled, North American Phase II LIBERTY trial, which is evaluating thrice-daily 150 mg Bestatin...
BioCentury | Sep 1, 2016
Distillery Therapeutics

Therapeutics: Lipoteichoic acid (LTA); heparin-binding EGF-like growth factor (HBEGF; DTR)

...Infectious disease INDICATION: Clostridium Mouse studies suggest LTA glycan-based vaccines could help prevent Clostridium difficile infection...
...from C. difficile LTA conjugated to the immunogenicity-enhancing carrier protein HBEGF increased serum levels of LTA...
...toxins A and B from C. difficile, in Phase II testing for CDI. TARGET/MARKER/PATHWAY: Lipoteichoic acid (LTA...
BioCentury | Aug 8, 2016
Clinical News

Bestatin ubenimex: Phase II started

Eiger began the double-blind, placebo-controlled, U.S. Phase II ULTRA trial to evaluate thrice-daily 150 mg oral Bestatin ubenimex for 24 weeks in about 40 patients. In 2015, Nippon granted Eiger rights to develop Bestatin for...
BioCentury | Dec 14, 2015
Company News

Nippon Kayaku, Eiger deal

Nippon granted Eiger rights to develop Bestatin ubenimex for pulmonary arterial hypertension (PAH) and inflammatory diseases that involve leukotriene B4 (LTB4) . Nippon markets Bestatin in Japan as an adjunct to chemotherapy agents for non-lymphocytic leukemia....
Items per page:
1 - 10 of 59